Pulse Biosciences, Inc. (PLSE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Pulse Biosciences, Inc. (PLSE) is up 76.8% since the beginning of the year. At $24 per share, PLSE is trading 13.2% below its 52-week high of $28. Investors who bought $1,000 worth of PLSE shares 5 years ago would now be looking at an investment worth $1,290.

Pulse Biosciences, Inc. (PLSE) has returned 76.84% so far this year and 43.84% over the past 12 months. Looking at the last ten years, PLSE has achieved an annualized return of 18.68%, outperforming the S&P 500 Index benchmark, which averaged 13.75% per year.

Based on dividend-adjusted daily data since May 18, 2016, PLSE's average daily return is +0.23%, while the average monthly return is +4.64%. At this rate, an investment would double in approximately 1.3 years.

Historically, 49% of months were positive and 51% were negative. The best month was Feb 2017 with a return of +105.2%, while the worst month was Feb 2022 at -58.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.

On a daily basis, PLSE closed higher 48% of trading days. The best single day was Feb 6, 2026 with a return of +51.6%, while the worst single day was Feb 8, 2022 at -34.4%.

Pulse Biosciences, Inc. has an annualized alpha of 50.03%, beta of 1.21, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 19, 2016.

• This stock captured 184.26% of S&P 500 Index gains and 154.37% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PLSE ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Pulse Biosciences, Inc. (PLSE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pulse Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pulse Biosciences, Inc. was 97.22%, occurring on Aug 30, 2022. The portfolio has not yet recovered.

The current Pulse Biosciences, Inc. drawdown is 45.15%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pulse Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pulse Biosciences, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.